Mogotes Metals Inc. press release
Today's Research Reports on TSO3, BELLUS Health, Immunovaccine and Microbix Biosystems Inc.
TSXV - TSX Venture Exchange · Copper · Gold · Silver · Molybdenum · Zinc · Lead · Arsenic · Antimony · Barium · Bismuth · Canada
Today’s Research Reports on TSO3, BELLUS Health, Immunovaccine and Microbix Biosystems Inc.
NEW YORK, NY / ACCESSWIRE / January 19, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.comand get exclusive access to our numerous research reports and market updates.
RDI has Initiated Coverage Today on:
TSO3 Inc. https://rdinvesting.com/news/?ticker=TOS.TO
BELLUS Health Inc. https://rdinvesting.com/news/?ticker=BLU.TO
Immunovaccine Inc. https://rdinvesting.com/news/?ticker=IMV.TO
Microbix Biosystems Inc. https://rdinvesting.com/news/?ticker=MBX.TO
TSO3's stock moved 2.32% lower Thursday, to close the day at $2.53. The stock recorded a trading volume of 118,485 shares, which was above its three months average volume of 113,577 shares. In the last year, TSO3's shares have traded in a range of 2.05 - 3.36. The share price has gained 23.41% from its 52-week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $2.58 is below its 200-day moving average of $2.71. Shares of TSO3 have fallen approximately 3.07 percent year-to-date.
Access RDI'sTSO3 Inc. Research Report at: https://rdinvesting.com/news/?ticker=TOS.TO
On Thursday, shares of BELLUS Health recorded a trading volume of 57,000 shares, which was above the three months average volume of 51,406 shares. The stock ended the day 2.50% higher at 0.41. The share price has gained 70.83% from its 52-week low with a 52-week trading range of 0.24 - 0.55.The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.40 is at its 200-day moving average of $0.40. Shares of BELLUS Health have gained approximately 10.81 percent year-to-date.
Access RDI'sBELLUS Health Inc. Research Report at: https://rdinvesting.com/news/?ticker=BLU.TO
Immunovaccine's stock moved 2.87% higher Thursday, to close the day at $2.15. The stock recorded a trading volume of 207,156 shares, which was above its three months average volume of 183,920 shares. In the last year, Immunovaccine's shares have traded in a range of 0.66 - 2.55. The share price has gained 225.76% from its 52-week low. The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $2.16 is greater than its 200-day moving average of $1.49. Shares of Immunovaccine have fallen approximately 8.51 percent year-to-date.
Access RDI'sImmunovaccine Inc. Research Report at: https://rdinvesting.com/news/?ticker=IMV.TO
On Thursday, shares in Microbix Biosystems recorded a trading volume of 8,200 shares, which was below the three months average volume of 39,163 shares. The stock ended the day 1.72% lower at 0.28. The share price has gained 29.55% from its 52-week low with a 52-week trading range of 0.22 - 0.40.The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.30 is below its 200-day moving average of $0.32. Shares of Microbix Biosystems have fallen approximately 6.56 percent year-to-date.
Access RDI'sMicrobix Biosystems Inc. Research Report at: https://rdinvesting.com/news/?ticker=MBX.TO
Our Actionable Research on TSO3 Inc. (TSX :TOS.TO), BELLUS Health Inc. (TSX :BLU.TO), Immunovaccine Inc. (TSX :IMV.TO) and Microbix Biosystems Inc. (TSX :MBX.TO) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
[
contact@rdinvesting.com
](mailto:contact@rdinvesting.com)
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com